Repurposing Research for Chicago 2026: Track 2 – Patient Groups supports Chicago-area researchers testing existing therapies for unsolved diseases in underserved groups, children, rare disease patients, and military groups.
Funder: Cures Within Reach
Due Dates (Anticipated): May 2027 (LOI, anticipated)
Funding Amounts: Trial budgets up to $125,000, including a 20% institutional match, for up to 36 months; additional community engagement support available
Summary: Supports Chicago-area clinical trials repurposing existing therapies for health disparities, pediatric patients, rare diseases, and veterans or active military.
Key Information: CWR funding must be the sole, late, or final funding needed to accomplish the proposed aims.
Cures Within Reach’s Patient Groups track supports interventional clinical repurposing trials at greater Chicago-area research institutions. Trials must address unsolved diseases affecting health disparities, pediatric patients, people with rare diseases, or veterans and active US military personnel. Eligible therapies include drugs, devices, nutraceuticals, diagnostics, and combinations already approved or recognized as safe for human use by a regulatory agency, tested in a new indication. Therapies may also be added to standard care to improve outcomes or quality of life.
The strongest preference is for proof-of-concept, pivotal, Phase I, or Phase IIA trials supported by preclinical evidence, real-world evidence, AI/machine-learning drug–disease matching, or clinical observations. CWR seeks robust, well-defined outcomes demonstrating reproducible clinical impact or generating data for follow-on funding and trials. Later-stage trials needing additional funding may also be considered.